Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes.

Ther Adv Med Oncol · 2022 · PMC8928350 · PMID 35309086

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The median OS in the BRCA/PALB2 -mutated group was higher for platinum-based regimens than non-platinum-based regimens (22.9 versus 9.0 months, HR = 0.31, 95% CI = 0.08–1.16, p = 0.08); however, this trend did not reach statistical significance ( Figure 3(a) ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.